

Post MI Prevalence: 2025 male 0.10 Baseline Lifestyle Outreach 0.08 Polypill 0.06 0.04 0.02 0.00 40_to_44 -95_plus -90_to_94 -45_to_49 -75_to_79 · 65_to_69 35_to_39 70_to_74 85_to_89 30_to_34 50_to_54 55_to_59 60_to_64 80_to_84 25_to_29

Post MI Prevalence: 2026 male 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -90_to_94 -45_to_49 -75_to_79 · 65_to_69 35_to_39 60_to_64 70_to_74 85_to_89 25_to_29 30_to_34 50_to_54 55_to_59 80_to_84

Post MI Prevalence: 2027 male 0.10 Baseline Lifestyle Outreach 0.08 Polypill 0.06 0.04 0.02 0.00 95_plus -90_to_94 -45_to_49 -75_to_79. 40_to_44 65_to_69 35_to_39 70_to_74 85_to_89 25_to_29 30_to_34 50_to_54 55_to_59 60_to_64 80_to_84


Post MI Prevalence: 2028 male 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -75_to_79 -65_to_69 90_to_94 35_to_39 45_to_49 55_to_59 70_to_74 85_to_89 25_to_29 30_to_34 50_to_54 60_to_64 80_to_84


Post MI Prevalence: 2029 male 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -90_to_94 -45_to_49 -75_to_79. 65_to_69 35_to_39 70_to_74 85_to_89 25_to_29 30_to_34 50_to_54 55_to_59 60_to_64 80_to_84


Post MI Prevalence: 2030 male 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -90_to_94 -45_to_49 -75_to_79. 65_to_69 35_to_39 70_to_74 85_to_89 25_to_29 30_to_34 50_to_54 55_to_59 60_to_64 80_to_84


Post MI Prevalence: 2031 male 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -65_to_69 90_to_94 30_to_34 35_to_39 45_to_49 70_to_74 85_to_89 25_to_29 50_to_54 55_to_59 60_to_64 75_to_79 80_to_84

Post MI Prevalence: 2032 male Baseline 0.10 Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -75_to_79 -65_to_69 90_to_94 30_to_34 35_to_39 45_to_49 70_to_74 85_to_89 25_to_29 50_to_54 55_to_59 60_to_64 80_to_84









Post MI Prevalence: 2037 male 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -65_to_69 90_to_94 30_to_34 35_to_39 45_to_49 70_to_74 85_to_89 25_to_29 50_to_54 55_to_59 60_to_64 75_to_79 80_to_84

Post MI Prevalence: 2038 male 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -65_to_69 90_to_94 30_to_34 35_to_39 45_to_49 55_to_59 70_to_74 85_to_89 25_to_29 50_to_54 60_to_64 75_to_79 80_to_84

Post MI Prevalence: 2039 male 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -45_to_49 -75_to_79 -65_to_69 90_to_94 30_to_34 35_to_39 60_to_64 70_to_74 85_to_89 25_to_29 50_to_54 55_to_59 80_to_84

Post MI Prevalence: 2040 male 0.10 Baseline Lifestyle Outreach 0.08 Polypill 0.06 0.04 0.02 0.00 40_to_44 | 95_plus -45_to_49 -75_to_79 -65_to_69 90_to_94 35_to_39 60_to_64 70_to_74 85_to_89 25_to_29 30_to_34 50_to_54 55_to_59 80_to_84